Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552755 · ClinicalTrials.gov registry record · Phase 1
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
A Phase 1 study of Familial Adenomatous Polyposis, sponsored by Recursion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 17
- Study locations
NCT05552755: Recruiting Phase 1 study of Familial Adenomatous Polyposis, sponsored by Recursion Pharmaceuticals.
NCT05552755 is a Phase 1 study of Familial Adenomatous Polyposis that is actively recruiting participants, run by Recursion Pharmaceuticals. The registered enrollment target is 67 participants, below the 242-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552755, a Phase 1 study of Familial Adenomatous Polyposis, is actively recruiting participants, sponsored by Recursion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multicenter, two-part trial in participants with FAP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REC-4881
Study Locations (17)
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
- Del Sol Research Management - Tucson
Florida
- GI Pros - Naples
- Digestive and Liver Center of Florida - Orlando
Tennessee
- Gastro One-8110 Walnut Rs - Cordova
- Vanderbilt Digestive Center - Nashville
Texas
- Genetic Cancer Prevention Clinic - UT Southwestern - Dallas
- MD Anderson Cancer Center - Houston
California
- Medical Associates Research Group - San Diego
Indiana
- Gastroenterology Health Partners, PLLC - New Albany
Louisiana
- Tandem Clinical Research - Marrero
Michigan
- Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis) - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT05552755 shows while recruiting
NCT05552755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 242-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Familial Adenomatous Polyposis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05552755 lists 17 locations in 13 states (Arizona, Florida, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05552755 about?
NCT05552755 is a clinical study titled "Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)". This is a multicenter, two-part trial in participants with FAP.
What is the current status of trial NCT05552755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-07-10. Estimated completion is 2026-07.
What conditions does trial NCT05552755 study?
This clinical trial studies the following conditions: Familial Adenomatous Polyposis.
What interventions are being tested in trial NCT05552755?
The interventions under investigation include: Placebo (DRUG), REC-4881 (DRUG).
Who is sponsoring clinical trial NCT05552755?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552755 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Adenomatous Polyposis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05552755's enrollment target sits among peer trials
67 4th of 10 higher than 7 of 10 other Familial Adenomatous Polyposis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Familial Adenomatous Polyposis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RECRUITING · Phase 1
-
A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
RECRUITING
-
A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
RECRUITING
-
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
RECRUITING · NA
-
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)
RECRUITING · NA
-
CryoBalloon Ablation for Treatment of Duodenal Adenomas
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI